固德威(688390.SH)2021年擬向金融機構申請新增不超3億元綜合授信額度
格隆匯9月3日丨固德威(688390.SH)公佈,公司於2021年9月3日召開了第二屆董事會第二十二次會議,審議通過了《關於新增預計公司及子公司2021年向金融機構申請綜合授信額度的議案》。
為滿足公司及子公司的日常生產經營及相關項目建設、投資等的資金需求,保證公司及子公司各項業務正常開展,該次擬新增預計公司及子公司2021年度向金融機構申請不超過人民幣3億元的綜合授信額度,授信業務包括但不限於申請貸款、承兑匯票、貿易融資、信用證、保函等。
該次申請綜合授信額度的決議有效期為自公司第二屆董事會第二十二次會議審議通過之日起至公司2021年年度股東大會召開之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.